EUVIMEDEUVIMED entdecken
Kohortenstudie

Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study

Victoria Ferrari, Lucas Morand, Hervé Hyvernat, Renaud Schiappa, Jean Dellamonica, Nihal Martis

Chemotherapy · 2024

DOI: 10.1159/000542101 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Chemotherapy, 2024. Verfasst von Victoria Ferrari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France. Hauptthemen laut MEDLINE: Neoplasms, Critical Care, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Our study aimed to identify relevant features associated with the reprisal of antineoplastic treatment in patients with solid cancers after unplanned admittance to the intensive care unit (ICU) and to assess 60th-month survival in patients with solid neoplasms admitted to the ICU.

Methods

This single-centre retrospective study of critically ill patients with active cancers was performed over a 13-year period (2005–2018). Patients’ characteristics, overall survival, and antineoplastic treatment reprisal were extracted from digital medical files and compared.

Results

134 patients were included in the study. Solid neoplasms were mostly localised to the head and neck (n = 53) followed by lung cancers (n = 29). Sepsis was the leading cause of ICU admission (62.1%) with 41/82 patients presenting with septic shock. Antineoplastic treatments were resumed in 40 patients. An age ≤60 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 were found to be predictors for treatment reprisal, with odd ratios of, respectively, 2.83 (95% CI, 1.15–6.99) and 5.45 (95% CI, 2.01–14.82); area under the ROC curve of 72% (95% CI, 63–81%). Survival after the immediate discharge from the ICU was 101/134 (75%) and the 60-month survival rate was 29% and significantly higher in the treatment-reprisal group.

Conclusions

Age and ECOG PS were found to be predictors for treatment reprisal in patients with solid neoplasms admitted to the ICU. The latter benefits from better long-term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCritical CareAntineoplastic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedIntensive Care UnitsAdultCohort StudiesCritical Illness

Stichwörter der Autor:innen

CancerIntensive carePrognosisSolid neoplasmSurvival

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France.
  • Department of Medical Intensive Care, Archet Hospital, Côte d'Azur University, Nice, France.
  • Epidemiology, Biostatistic and Health Data Department, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France.
  • Department of Internal Medicine and Clinical Immunology, Archet Hospital, Côte d'Azur University, Nice, France.

Zitieren

APA

Ferrari, V., Morand, L., Hyvernat, H., Schiappa, R., Dellamonica, J., & Martis, N. (2024). Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study. Chemotherapy. https://doi.org/10.1159/000542101

Vancouver

Ferrari V, Morand L, Hyvernat H, Schiappa R, Dellamonica J, Martis N. Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study. Chemotherapy. 2024. doi:10.1159/000542101

BibTeX
@article{Ferrari2024,
  author = {Ferrari, Victoria and Morand, Lucas and Hyvernat, Hervé and Schiappa, Renaud and Dellamonica, Jean and Martis, Nihal},
  title = {Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000542101}
}
Kostenlos starten →